search
Back to results

Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate (CITrUS)

Primary Purpose

Antimicrobial Prophylaxis in Prostate Surgery

Status
Recruiting
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)
oral applications of Placebo
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Antimicrobial Prophylaxis in Prostate Surgery focused on measuring Greenlight Laser Vaporisation of the Prostate, Transurethral resection of the prostate, Cotrimoxazole Prophylaxis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Obstructive voiding disorder (e.g. benign prostate hyperplasia, obstructive prostate cancer)
  • Planned Transurethral resection of the prostate (TURP) or Greenlight Laser (GL)

Exclusion Criteria:

  • Evidence for (catheter associated-) UTI, with or without antibiotic treatment in the last 7 days prior to randomisation.
  • Any evidence of a history of positive urine culture (cfu ³105/ml in midstream-urine with no more than two species) and resistance to TMP/SMX in the last 7 days prior to randomisation.
  • Known contraindication against study drugs according to the Swissmedic package leaflet (e.g. known liver dysfunction, renal insufficiency; patients with glomerular filtration rate (calculated by the Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <30ml/min or dialysis patients will be excluded).
  • Antibiotic treatment for any reason within 7 days prior to randomisation
  • Indication for Antibiotic prophylaxis (AP) for other reasons (e.g. endocarditis prophylaxis, transplanted patients under systemic immunosuppression).

Sites / Locations

  • St. Claraspital, Department of UrologyRecruiting
  • Kantonsspital Aarau, Department of UrologyRecruiting
  • University Hospital Basel, Division of Infectious Diseases and Hospital EpidemiologyRecruiting
  • Kantonsspital Baselland, Department of UrologyRecruiting
  • University Hospital Zurich, Department of Urology

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Group A

Group B

Arm Description

Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.

3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.

Outcomes

Primary Outcome Measures

Symptomatic UrinaryTract Infection (UTI)
Symptomatic UTI (based on clinical diagnosis) treated with antimicrobial agents

Secondary Outcome Measures

Symptomatic UTI by measured bacteriuria
measured bacteriuria of ≥105 cfu/ml treated with antimicrobial agents (key secondary outcome)
Symptomatic cystitis (based on clinical diagnosis)
Symptomatic cystitis (based on clinical diagnosis)
Symptomatic epididymitis (based on clinical diagnosis)
Symptomatic epididymitis (based on clinical diagnosis)
Symptomatic pyelonephritis (based on clinical diagnosis)
Symptomatic pyelonephritis (based on clinical diagnosis)
Symptomatic prostatitis (based on clinical diagnosis)
Symptomatic prostatitis (based on clinical diagnosis)
Symptomatic urethritis (based on clinical diagnosis)
Symptomatic urethritis (based on clinical diagnosis)
Urosepsis (based on clinical diagnosis)
Urosepsis (based on clinical diagnosis)
Prescription of antibiotics (for any reason)
Prescription of antibiotics (for any reason)
Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD) day 30)
Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD)
Asymptomatic bacteriuria of ≥105 cfu/ml treated with antimicrobial agents
Asymptomatic bacteriuria of ≥105 cfu/ml treated with antimicrobial agents
Detection of multidrug-resistant bacteria in Urine culture
Detection of multidrug-resistant bacteria in Urine culture
Any Clostridium difficile-associated infection
Any Clostridium difficile-associated infection
Duration of catheterisation (cumulative sum of days between randomisation and end of catheterisation or day 30)
Duration of catheterisation (cumulative sum of days between randomisation and end of catheterisation or day 30)
Duration of hospital stay (cumulative sum of Hospital days between randomisation and day 30)
Duration of hospital stay (cumulative sum of Hospital days between randomisation and day 30)
Duration of intensive care unit (ICU) stay (cumulative sum of ICU days between randomisation and day 30)
Duration of intensive care unit stay (cumulative sum of ICU days between randomisation and day 30)
Re-hospitalisation (within 30 days after randomisation)
Re-hospitalisation (within 30 days after randomisation)
Change of International Prostate Symptom Score (prior to randomisation and at day 30 after randomisation)
Change of International Prostate Symptom Score (prior to randomisation and at day 30 after randomisation)
Change of Quality of life Score (prior to randomisation and at day 30 after randomisation)
Change of Quality of life Score (prior to randomisation and at day 30 after randomisation)
All-cause mortality
All-cause mortality
Total adverse events
Total adverse events
Total serious adverse events
Total serious adverse events

Full Information

First Posted
August 14, 2018
Last Updated
May 2, 2022
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Swiss National Science Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT03633643
Brief Title
Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate
Acronym
CITrUS
Official Title
Single-Dose Versus 3-Day Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate: A Pragmatic, Multicentre Randomised Placebo Controlled Non-Inferiority Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 29, 2018 (Actual)
Primary Completion Date
October 31, 2022 (Anticipated)
Study Completion Date
October 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
Swiss National Science Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The optimal duration of antimicrobial prophylaxis (study medication Cotrimoxazole (Trimethoprim/Sulfamethoxazole)) in transurethral resection of the prostate and Greenlight Laser vaporisation of the prostate is investigated by comparing a guideline-conform single-dose prophylaxis (intervention) versus usual clinical care (i.e. 3-day prophylaxis; control) for prevention of urinary tract infections.
Detailed Description
Increasing antimicrobial resistance rates have a substantial impact on morbidity, mortality and healthcare costs and is particularly prevalent among urological patients due to an overuse of antimicrobial agents for therapeutical and prophylactic indications. Transurethral resection of the prostate is one of the most frequently performed urological procedures in Switzerland and a single-dose of antimicrobial prophylaxis is recommended to reduce postoperative urinary tract infections. For photoselective vaporisation of the prostate with the Greenlight Laser, a similar operative alternative, there are currently no international guidelines for antimicrobial prophylaxis. The optimal duration of antimicrobial prophylaxis in transurethral resection of the prostate and Greenlight Laser vaporisation of the prostate is investigated by comparing a guideline-conform single-dose prophylaxis (intervention) versus usual clinical care (i.e. 3-day prophylaxis; control) for prevention of urinary tract infections. The study medication Cotrimoxazole (Trimethoprim/Sulfamethoxazole) is a routinely used antimicrobial substance recommended in international and in-house guidelines for antimicrobial prophylaxis and treatment of urinary tract infections. Perioperative antimicrobial prophylaxis will be Cotrimoxazole short infusion in both groups. Postoperative study medication packages consists of either five tablets of placebo or five tablets of Cotrimoxazole (Nopil forte®) 800/160mg using licensed product repacked in a new immediate container which is blinded

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Antimicrobial Prophylaxis in Prostate Surgery
Keywords
Greenlight Laser Vaporisation of the Prostate, Transurethral resection of the prostate, Cotrimoxazole Prophylaxis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
single-dose application of Cotrimoxazole compared to a 3-day application of Cotrimoxazole
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1574 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Placebo Comparator
Arm Description
Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Intervention Type
Drug
Intervention Name(s)
oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)
Intervention Description
five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Intervention Type
Drug
Intervention Name(s)
oral applications of Placebo
Intervention Description
five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Primary Outcome Measure Information:
Title
Symptomatic UrinaryTract Infection (UTI)
Description
Symptomatic UTI (based on clinical diagnosis) treated with antimicrobial agents
Time Frame
within 30 days after randomization
Secondary Outcome Measure Information:
Title
Symptomatic UTI by measured bacteriuria
Description
measured bacteriuria of ≥105 cfu/ml treated with antimicrobial agents (key secondary outcome)
Time Frame
within 30 days after randomization
Title
Symptomatic cystitis (based on clinical diagnosis)
Description
Symptomatic cystitis (based on clinical diagnosis)
Time Frame
within 30 days after randomization
Title
Symptomatic epididymitis (based on clinical diagnosis)
Description
Symptomatic epididymitis (based on clinical diagnosis)
Time Frame
within 30 days after randomization
Title
Symptomatic pyelonephritis (based on clinical diagnosis)
Description
Symptomatic pyelonephritis (based on clinical diagnosis)
Time Frame
within 30 days after randomization
Title
Symptomatic prostatitis (based on clinical diagnosis)
Description
Symptomatic prostatitis (based on clinical diagnosis)
Time Frame
within 30 days after randomization
Title
Symptomatic urethritis (based on clinical diagnosis)
Description
Symptomatic urethritis (based on clinical diagnosis)
Time Frame
within 30 days after randomization
Title
Urosepsis (based on clinical diagnosis)
Description
Urosepsis (based on clinical diagnosis)
Time Frame
within 30 days after randomization
Title
Prescription of antibiotics (for any reason)
Description
Prescription of antibiotics (for any reason)
Time Frame
within 30 days after randomization
Title
Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD) day 30)
Description
Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD)
Time Frame
within 30 days after randomization
Title
Asymptomatic bacteriuria of ≥105 cfu/ml treated with antimicrobial agents
Description
Asymptomatic bacteriuria of ≥105 cfu/ml treated with antimicrobial agents
Time Frame
within 30 days after randomization
Title
Detection of multidrug-resistant bacteria in Urine culture
Description
Detection of multidrug-resistant bacteria in Urine culture
Time Frame
within 30 days after randomization
Title
Any Clostridium difficile-associated infection
Description
Any Clostridium difficile-associated infection
Time Frame
within 30 days after randomization
Title
Duration of catheterisation (cumulative sum of days between randomisation and end of catheterisation or day 30)
Description
Duration of catheterisation (cumulative sum of days between randomisation and end of catheterisation or day 30)
Time Frame
within 30 days after randomization
Title
Duration of hospital stay (cumulative sum of Hospital days between randomisation and day 30)
Description
Duration of hospital stay (cumulative sum of Hospital days between randomisation and day 30)
Time Frame
within 30 days after randomization
Title
Duration of intensive care unit (ICU) stay (cumulative sum of ICU days between randomisation and day 30)
Description
Duration of intensive care unit stay (cumulative sum of ICU days between randomisation and day 30)
Time Frame
within 30 days after randomization
Title
Re-hospitalisation (within 30 days after randomisation)
Description
Re-hospitalisation (within 30 days after randomisation)
Time Frame
within 30 days after randomization
Title
Change of International Prostate Symptom Score (prior to randomisation and at day 30 after randomisation)
Description
Change of International Prostate Symptom Score (prior to randomisation and at day 30 after randomisation)
Time Frame
within 30 days after randomization
Title
Change of Quality of life Score (prior to randomisation and at day 30 after randomisation)
Description
Change of Quality of life Score (prior to randomisation and at day 30 after randomisation)
Time Frame
within 30 days after randomization
Title
All-cause mortality
Description
All-cause mortality
Time Frame
within 30 days after randomization
Title
Total adverse events
Description
Total adverse events
Time Frame
within 30 days after randomization
Title
Total serious adverse events
Description
Total serious adverse events
Time Frame
within 30 days after randomization

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Obstructive voiding disorder (e.g. benign prostate hyperplasia, obstructive prostate cancer) Planned Transurethral resection of the prostate (TURP) or Greenlight Laser (GL) Exclusion Criteria: Evidence for (catheter associated-) UTI, with or without antibiotic treatment in the last 7 days prior to randomisation. Any evidence of a history of positive urine culture (cfu ³105/ml in midstream-urine with no more than two species) and resistance to TMP/SMX in the last 7 days prior to randomisation. Known contraindication against study drugs according to the Swissmedic package leaflet (e.g. known liver dysfunction, renal insufficiency; patients with glomerular filtration rate (calculated by the Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <30ml/min or dialysis patients will be excluded). Antibiotic treatment for any reason within 7 days prior to randomisation Indication for Antibiotic prophylaxis (AP) for other reasons (e.g. endocarditis prophylaxis, transplanted patients under systemic immunosuppression).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas Widmer, Prof.,MD,Dr.
Phone
+41 61 265 38 51
Email
andreas.widmer@usb.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Hans-Helge Seifert, PD,MD,Dr.
Phone
+41 61 265 38 51
Email
hans-helge.seifert@usb.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Widmer, Prof.,MD,Dr.
Organizational Affiliation
Division of Infectious Diseases and Hospital Epidemiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Claraspital, Department of Urology
City
Basel
State/Province
Basel Stadt
ZIP/Postal Code
4058
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Ardelt, Dr. med
Phone
+41 61 685 85 23
Facility Name
Kantonsspital Aarau, Department of Urology
City
Aarau
ZIP/Postal Code
5001
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maciej Kwiatkowski, Dr. med
Phone
+41 62 838 47 47
Facility Name
University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Widmer, Prof.Dr.med
Phone
+41 61 265 38 51
Email
andreas.widmer@usb.ch
First Name & Middle Initial & Last Name & Degree
Kathrin Bausch, Dr.med
Email
kathrin.bausch@usb.ch
Facility Name
Kantonsspital Baselland, Department of Urology
City
Liestal
ZIP/Postal Code
4410
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Svetozar Subotic, Dr. med
Phone
+41 61 925 21 72
Facility Name
University Hospital Zurich, Department of Urology
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Hermanns, PD Dr. med
Phone
+41 44 255 54 40

12. IPD Sharing Statement

Citations:
PubMed Identifier
30782183
Citation
Speich B, Bausch K, Roth JA, Hemkens LG, Ewald H, Vogt DR, Bruni N, Deuster S, Seifert HH, Widmer AF. Single-dose versus 3-day cotrimoxazole prophylaxis in transurethral resection or greenlight laser vaporisation of the prostate: study protocol for a multicentre randomised placebo controlled non-inferiority trial (CITrUS trial). Trials. 2019 Feb 19;20(1):142. doi: 10.1186/s13063-019-3237-3.
Results Reference
derived

Learn more about this trial

Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate

We'll reach out to this number within 24 hrs